149 related articles for article (PubMed ID: 33525262)
1. Synthesis, validation and quality controls of [68Ga]-DOTA-Pentixafor for PET imaging of chemokine receptor CXCR4 expression.
Sammartano A; Migliari S; Scarlattei M; Baldari G; Ruffini L
Acta Biomed; 2020 Jul; 91(4):e2020097. PubMed ID: 33525262
[TBL] [Abstract][Full Text] [Related]
2. Validation of Quality Control Parameters of Cassette-Based Gallium-68-DOTA-Tyr3-Octreotate Synthesis.
Sammartano A; Migliari S; Scarlattei M; Baldari G; Ruffini L
Indian J Nucl Med; 2020; 35(4):291-298. PubMed ID: 33642752
[TBL] [Abstract][Full Text] [Related]
3. A Rapid and Specific HPLC Method to Determine Chemical and Radiochemical Purity of [
Migliari S; Sammartano A; Scarlattei M; Baldari G; Silva C; Ruffini L
Curr Radiopharm; 2021; 14(2):121-130. PubMed ID: 32990551
[TBL] [Abstract][Full Text] [Related]
4. Automated synthesis and quality control of [
Daniel T; Balouzet Ravinet C; Clerc J; Batista R; Mouraeff Y
EJNMMI Radiopharm Chem; 2023 Feb; 8(1):4. PubMed ID: 36749409
[TBL] [Abstract][Full Text] [Related]
5. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.
Lapa C; Lückerath K; Rudelius M; Schmid JS; Schoene A; Schirbel A; Samnick S; Pelzer T; Buck AK; Kropf S; Wester HJ; Herrmann K
Oncotarget; 2016 Feb; 7(8):9288-95. PubMed ID: 26843617
[TBL] [Abstract][Full Text] [Related]
6. A Specific HPLC Method to Determine Residual HEPES in [
Migliari S; Scarlattei M; Baldari G; Silva C; Ruffini L
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889351
[TBL] [Abstract][Full Text] [Related]
7. Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer - a first clinical approach.
Linde P; Baues C; Wegen S; Trommer M; Quaas A; Rosenbrock J; Celik E; Marnitz S; Bruns CJ; Fischer T; Schomaecker K; Wester HJ; Drzezga A; van Heek L; Kobe C
Cancer Imaging; 2021 Feb; 21(1):22. PubMed ID: 33579381
[TBL] [Abstract][Full Text] [Related]
8. [
Costes J; Casasagrande K; Dubegny C; Castillo J; Kaufman J; Masset J; Vriamont C; Warnier C; Faivre-Chauvet A; Delage JA
J Labelled Comp Radiopharm; 2023 Oct; 66(12):400-410. PubMed ID: 37679888
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
[TBL] [Abstract][Full Text] [Related]
10. The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism.
Zheng Y; Long T; Peng N; Zhen M; Ye Q; Zhang Z; He Y; Chen Z; Gan Y; Luo M; Li C; Liu Z; Guo M; Wang M; Luo X; Hu S; Liu L; Jiang T
J Clin Endocrinol Metab; 2023 Dec; 109(1):171-182. PubMed ID: 37477496
[TBL] [Abstract][Full Text] [Related]
11. [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques.
Li X; Heber D; Leike T; Beitzke D; Lu X; Zhang X; Wei Y; Mitterhauser M; Wadsak W; Kropf S; Wester HJ; Loewe C; Hacker M; Haug AR
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):558-566. PubMed ID: 28932900
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT.
Bouter Y; Meller B; Sahlmann CO; Wolf BJ; Langer L; Bankstahl JP; Wester HJ; Kropf S; Meller J; Bouter C
Nuklearmedizin; 2018 Sep; 57(5):198-203. PubMed ID: 30267402
[TBL] [Abstract][Full Text] [Related]
13. (68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.
Lapa C; Lückerath K; Kleinlein I; Monoranu CM; Linsenmann T; Kessler AF; Rudelius M; Kropf S; Buck AK; Ernestus RI; Wester HJ; Löhr M; Herrmann K
Theranostics; 2016; 6(3):428-34. PubMed ID: 26909116
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Central Nervous System Lymphoma Based on CXCR4 Expression In Vivo Using 68Ga-Pentixafor PET/MRI.
Starzer AM; Berghoff AS; Traub-Weidinger T; Haug AR; Widhalm G; Hacker M; Rausch I; Preusser M; Mayerhoefer ME
Clin Nucl Med; 2021 Jan; 46(1):16-20. PubMed ID: 33208624
[TBL] [Abstract][Full Text] [Related]
15. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
16. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma.
Kiran MY; Apaydin Arikan E; Sanli Y; Yegen G; Kuyumcu S
Clin Nucl Med; 2021 Dec; 46(12):e563-e564. PubMed ID: 34269725
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor.
Herrmann K; Lapa C; Wester HJ; Schottelius M; Schiepers C; Eberlein U; Bluemel C; Keller U; Knop S; Kropf S; Schirbel A; Buck AK; Lassmann M
J Nucl Med; 2015 Mar; 56(3):410-6. PubMed ID: 25698782
[TBL] [Abstract][Full Text] [Related]
19. Molecular Imaging of Chemokine Receptor CXCR4 in Non-Small Cell Lung Cancer Using 68Ga-Pentixafor PET/CT: Comparison With 18F-FDG.
Derlin T; Jonigk D; Bauersachs J; Bengel FM
Clin Nucl Med; 2016 Apr; 41(4):e204-5. PubMed ID: 26756098
[TBL] [Abstract][Full Text] [Related]
20. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
